BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,606,384 | +10.6% | 23,599 | +32.6% | 0.01% | 0.0% |
| Q2 2023 | $1,452,524 | +60.6% | 17,794 | +46.0% | 0.01% | +50.0% |
| Q1 2023 | $904,228 | +1570.8% | 12,188 | +1766.5% | 0.00% | – |
| Q4 2022 | $54,121 | -89.4% | 653 | -63.6% | 0.00% | -100.0% |
| Q3 2022 | $509,000 | -19.1% | 1,794 | -1.2% | 0.00% | -20.0% |
| Q2 2022 | $629,000 | -91.4% | 1,815 | -89.2% | 0.01% | -91.7% |
| Q1 2022 | $7,302,000 | +60.3% | 16,863 | +91.6% | 0.06% | +27.7% |
| Q4 2021 | $4,554,000 | +256.9% | 8,803 | +234.2% | 0.05% | +193.8% |
| Q3 2021 | $1,276,000 | -30.8% | 2,634 | -35.7% | 0.02% | -38.5% |
| Q2 2021 | $1,844,000 | +16.6% | 4,095 | -1.2% | 0.03% | -3.7% |
| Q1 2021 | $1,582,000 | +24.7% | 4,143 | +3.7% | 0.03% | +12.5% |
| Q4 2020 | $1,269,000 | -42.4% | 3,996 | -55.0% | 0.02% | -48.9% |
| Q3 2020 | $2,202,000 | -22.6% | 8,889 | -31.4% | 0.05% | -63.6% |
| Q4 2019 | $2,845,000 | +4.2% | 12,960 | -7.1% | 0.13% | +111.5% |
| Q3 2019 | $2,730,000 | -12.9% | 13,952 | -7.2% | 0.06% | -20.8% |
| Q2 2019 | $3,134,000 | +12.4% | 15,032 | +10.1% | 0.08% | -26.7% |
| Q3 2018 | $2,788,000 | +58.6% | 13,658 | +14.9% | 0.10% | +31.2% |
| Q2 2018 | $1,758,000 | +14.5% | 11,884 | +16.8% | 0.08% | -5.9% |
| Q1 2018 | $1,536,000 | +31.4% | 10,172 | +12.7% | 0.08% | +3.7% |
| Q4 2017 | $1,169,000 | +99.5% | 9,024 | +86.2% | 0.08% | +57.7% |
| Q3 2017 | $586,000 | +14.7% | 4,846 | +11.5% | 0.05% | +2.0% |
| Q2 2017 | $511,000 | +20.5% | 4,346 | +4.2% | 0.05% | -1.9% |
| Q1 2017 | $424,000 | +21.1% | 4,171 | +22.5% | 0.05% | +4.0% |
| Q4 2016 | $350,000 | -1.7% | 3,406 | +4.8% | 0.05% | -7.4% |
| Q3 2016 | $356,000 | +9.9% | 3,249 | +13.2% | 0.05% | +5.9% |
| Q2 2016 | $324,000 | – | 2,870 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |